Aug 2026· British Journal of Cancer· 0 citations· 28 references
Medicine
TL;DR
An internally validated prediction model for BrM in GI cancers developed and validated performance in a held-out cohort to develop a clinically interpretable prediction model.
Among patients treated with NAC for early-stage BC, residual nodal disease, inflammatory BC, and HER2+ or triple-negative subtype are associated with a higher risk of BrM development and whether BrM screening is warranted among patients with these high-risk features warrants evaluation.
Jie Zhu, I. Fernandes, Júlia Belone Lopes et al.· Journal of Neuro-Oncology· 0 citations
This ML-based prediction model may help quantify the risk of early death in LCBM patients after radiotherapy, providing references for clinicians to improve prognostic evaluation and optimize treatment strategies.
Ru Song, Zhi-Jun Zhang, Xia-Oou Huo et al.· Journal of Thoracic Disease· 0 citations
In this large population-based cohort study, baseline obesity was not associated with risk of BrM, however, BMI when measured as a continuous variable, was associated with a significantly shorter time-to-development of BrM, a finding that warrants further study.
C. Murphy, Bo Zhang, Júlia Belone Lopes et al.· Neuro-Oncology Advances· 0 citations
OBJECTIVE
The objective of the present study was to explore the prevalence, risk and prognostic factors for bone metastases (BM) developement in patients with initial gastric cancer (GC).
METHODS
A total of 30,817 patients with GC in the Surveillance, Epidemiology and End Results (SEER) database, diagnosed from 2010...
Thanh Tùng Hoàng, Tuấn Sỹ Anh Bùi, Manh Nguyen et al.· Asian Pacific Journal of Can...· 0 citations
A clinical predictive model was established to estimate 3-, 4-, and 5-year survival rates for LACSC patients and exhibited significantly poorer overall survival in both cohorts (P < 0.05).
Ting-Ting Zou, Xu-Peng Wang, Hai-Xia Wu et al.· Frontiers in Oncology· 0 citations
A clinical model incorporating age (≥65 years), T stage (T3/T4), N stage (N2/N3), and chemotherapy (no) was developed to predict inferior OS in early-stage MedBC.
Y. Tan, X. Tian, Q. Li et al.· Hong Kong medical journal =...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.